Business
Interim report: Six months to 30 September 2025
EDX Medical Group plc reported a loss for the six months ended September 30, 2025, of £2,292,168, an increase from the £1,699,298 loss in the prior year period, with administrative expenses rising due to investment in cancer diagnostics. The company experienced a delay in European market product availability affecting forecast revenues, though this has been resolved. Key developments included progress on prostate and testicular cancer diagnostics, a public-private partnership for a pneumonia test for NHS patients, and a memorandum of understanding with Spire Healthcare Group plc. The company's cash balance significantly decreased to £124,794 from £2,308,069, and net assets fell to £510,740 from £1,784,459. Disclaimer*
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\n \nThe information contained in this announcement is deemed to constitute inside information as stipulated under Article 7 of the Market Abuse Regulation (EU No. 596/2014).\n \n \n19 December 2025\nEDX Medical Group plc · EDX\n \nInterim report: Six months to 30 September 2025\n \nCAMBRIDGE, UK: EDX Medical Group Plc (AQSE: EDX) (\"EDX Medical\" or the \"Company\"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has today published its Interim Report and Financial Statements for the six-month period ended September 20, 2025. The full report can be be viewed below and electronic copies are available on the Company's website at: https://edxmedical.co.uk/documents/\n \nStatement by Jason Holt, chairman, EDX Medical:\n\"During the reporting period, EDX Medical continued to strengthen its operational and commercial capabilities to further the provision of innovative digital diagnostics products addressing major diseases such as cancer, cardiovascular illness and infectious diseases.\n \n\"The Company continued its development of class-leading oncology diagnostics, particularly for prostate cancer. It also embarked on a significant public-private partnership to provide a new pneumonia test for critically ill NHS patients and progressed its relationship with a leading private healthcare provider in the UK.\n \n\"The Company made further investment in its cancer testing programmes with the recruitment of laboratory staff and extra development expenditure. This resulted in higher-than-expected administrative expenditure. In respect of revenues, the Company encountered a delay in some product availability in the European market, which affected forecast revenues. These matters have been resolved and significant revenues from existing products and those in development, are expected going forward.\n \n\"The Company is confident its dual 'commercial and development' strategy and the quality of diagnostic products will serve it well in a fast-growing global market.\"\n \nKey developments within the reporting period included:\n \n· Prostate cancer diagnostics programme expanded to include the development of a labora...